Education
About Us
Working with TipRanks
Follow Us
Edward Kaye Insider Profile
11 Followers
Edward Kaye, Director at Sarepta Therapeutics, holds 29.99K shares in Cytokinetics (Ticker: CYTK), holds 6.69K shares in Avidity Biosciences (Ticker: RNA), holds 139.35K shares in Stoke Therapeutics (Ticker: STOK).
Profitable Transactions
1 out of 4 Profitable Transactions
Average Return
-18.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Edward Kaye holds in companies
Most Profitable Insider Trade
The most profitable trade made by Edward Kaye
Edward Kaye's Trading History
Sarepta Therapeutics
Aug 07, 2017
Director
Uninformative Buy
710.55K
$1.13M
Cytokinetics
Jul 16, 2025
Director
Uninformative Buy
12.47K
$1.10M
Stoke Therapeutics
Mar 20, 2025
Director
Informative Sell
163.67K
$1.80M
Avidity Biosciences
Jun 12, 2025
Director
Uninformative Buy
―
$240.38K
List of latest transactions for each holding click on a transaction to see Edward Kaye's performance on stock
You May Also Like
Edward Kaye insider profile FAQ
What is the percentage of profitable transactions made by Edward Kaye?
The percentage of profitable transactions made by Edward Kaye is 25%.
What is the average return per transaction made by Edward Kaye?
The average return per transaction made by Edward Kaye is -18.10%.
What stocks does Edward Kaye hold?
Edward Kaye holds: SRPT, CYTK, STOK, RNA stocks.
What was Edward Kaye’s latest transaction?
Edward Kaye latest transaction was an Uninformative Buy of $12.47K.
What was Edward Kaye's most profitable transaction?
Edward Kaye’s most profitable transaction was an Informative Sell of STOK stock on December 10, 2024. The return on the trade was 1.20%.
What is Edward Kaye's role in Sarepta Therapeutics?
Edward Kaye's role in Sarepta Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.